The new RSV vaccines for older adults - Mayo Clinic Press
Sep 19, 2023 · In May 2023, pharmaceutical companies GSK and Pfizer received approval from the U.S. Food and Drug Administration (FDA) for their RSV vaccines within weeks of each other. Both vaccines are currently available. Here’s what you need to know about RSV and the two new vaccines designed to protect against it.
CDC Updates RSV Vaccination Recommendation for Adults
Jun 26, 2024 · Today, CDC updated its recommendation for the use of Respiratory Syncytial Virus (RSV) vaccines in people ages 60 and older. For this upcoming respiratory virus season, CDC recommends: Everyone ages 75 and older receive the RSV vaccine.
RSV Vaccine Guidance for Older Adults | RSV | CDC
CDC recommends a single dose of RSV vaccine for older adults to help prevent serious RSV infection and hospitalization. RSV vaccination is recommended for the following adults: All adults ages 75 and older. Adults ages 60–74 at increased risk of severe RSV disease.
New RSV Vaccine Distribution: Who’s at the Top of the List?
Oct 28, 2024 · Does the new RSV vaccine have any side effects? In adults, the most frequently reported side effects have been soreness at the injection site, muscle pain, fatigue, headache and joint pain. In the combined clinical trials of the vaccine, 20 out of more than 38,000 people who received the shot reported an abnormal heart rate about two weeks ...
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults …
Oct 22, 2024 · ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age.
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...
Arexvy Looks Promising for RSV Protection in Younger At-Risk and ...
1 day ago · The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial (ClinicalTrials.gov Identifier: NCT06389487). Findings showed a single dose of Arexvy elicited a noninferior immune response in this patient population ...
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
Dec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F...
FDA approves Moderna’s mRNA RSV vaccine for older adults
May 31, 2024 · The US Food and Drug Administration has approved another vaccine that can help protect older people from respiratory syncytial virus, known as RSV. The shot, made by Moderna and sold under the name...
FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
May 3, 2023 · The US Food and Drug Administration approved the first vaccine against respiratory syncytial virus, known as RSV, and vaccines are in the works.